140 related articles for article (PubMed ID: 38477065)
1. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
[TBL] [Abstract][Full Text] [Related]
2. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA
Amyloid; 2021 Mar; 28(1):50-55. PubMed ID: 32883119
[TBL] [Abstract][Full Text] [Related]
3. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis?
Romano A; Primiano G; Antonini G; Ceccanti M; Fenu S; Forcina F; Gentile L; Inghilleri M; Leonardi L; Manganelli F; Obici L; Sabino A; Sciarrone MA; Tozza S; Vitali F; Luigetti M
Eur J Neurol; 2024 Jan; 31(1):e16070. PubMed ID: 37724995
[TBL] [Abstract][Full Text] [Related]
4. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice.
Carroll AS; Razvi Y; O'Donnell L; Veleva E; Heslegrave A; Zetterberg H; Vucic S; Kiernan MC; Rossor AM; Gillmore JD; Reilly MM
Amyloid; 2024 Jun; 31(2):95-104. PubMed ID: 38348665
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
Ticau S; Sridharan GV; Tsour S; Cantley WL; Chan A; Gilbert JA; Erbe D; Aldinc E; Reilly MM; Adams D; Polydefkis M; Fitzgerald K; Vaishnaw A; Nioi P
Neurology; 2021 Jan; 96(3):e412-e422. PubMed ID: 33087494
[TBL] [Abstract][Full Text] [Related]
6. Serum neurofilament light chain levels correlate with small fiber related parameters in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
Galosi E; Costanzo R; Forcina F; Morino S; Antonini G; Salvetti M; Lauletta A; Luigetti M; Romano A; Primiano G; Guglielmino V; Fionda L; Garibaldi M; Esposito N; Falco P; di Pietro G; Truini A; Leonardi L
Neurol Sci; 2024 May; ():. PubMed ID: 38700599
[TBL] [Abstract][Full Text] [Related]
7. Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study.
Fargeot G; Echaniz-Laguna A; Labeyrie C; Svahn J; Camdessanché JP; Cintas P; Chanson JB; Esselin F; Piedvache C; Verstuyft C; Genestet S; Lagrange E; Magy L; Péréon Y; Sacconi S; Signate A; Nadaj-Pakleza A; Taithe F; Viala K; Tard C; Poinsignon V; Cauquil C; Attarian S; Adams D
Amyloid; 2024 Mar; 31(1):62-69. PubMed ID: 37855400
[TBL] [Abstract][Full Text] [Related]
8. A natural history analysis of asymptomatic
Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
[TBL] [Abstract][Full Text] [Related]
9. Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis-A Swiss reference center experience.
Loser V; Benkert P; Vicino A; Lim Dubois Ferriere P; Kuntzer T; Pasquier J; Maceski A; Kuhle J; Theaudin M
J Peripher Nerv Syst; 2023 Mar; 28(1):86-97. PubMed ID: 36471582
[TBL] [Abstract][Full Text] [Related]
10. Neurofilament Light Chains in Systemic Amyloidosis: A Systematic Review.
Berends M; Nienhuis HLA; Adams D; Karam C; Luigetti M; Polydefkis M; Reilly MM; Sekijima Y; Hazenberg BPC
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612579
[TBL] [Abstract][Full Text] [Related]
11. Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis.
Kollmer J; Hegenbart U; Kimmich C; Hund E; Purrucker JC; Hayes JM; Lentz SI; Sam G; Jende JME; Schönland SO; Bendszus M; Heiland S; Weiler M
Ann Clin Transl Neurol; 2020 May; 7(5):799-807. PubMed ID: 32333729
[TBL] [Abstract][Full Text] [Related]
12. Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.
Beauvais D; Labeyrie C; Cauquil C; Francou B; Eliahou L; Not A; Echaniz-Laguna A; Adam C; Slama MS; Benmalek A; Leonardi L; Rouzet F; Adams D; Algalarrondo V; Beaudonnet G
J Neurol Neurosurg Psychiatry; 2024 May; 95(6):489-499. PubMed ID: 37875336
[TBL] [Abstract][Full Text] [Related]
13. Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis.
Lau KHV; Prokaeva T; Zheng L; Doros G; Kaku MC; Spencer B; Berk J; Sanchorawala V
Amyloid; 2024 Jun; 31(2):150-152. PubMed ID: 38073425
[No Abstract] [Full Text] [Related]
14. Dual-Echo Turbo Spin Echo and 12-Echo Multi Spin Echo Sequences as Equivalent Techniques for Obtaining T2-Relaxometry Data: Application in Symptomatic and Asymptomatic Hereditary Transthyretin Amyloidosis as a Surrogate Disease.
Poncelet A; Weiler M; Hegenbart U; Sam G; Schönland S; Purrucker JC; Hayes JM; Hund E; Bendszus M; Heiland S; Kollmer J
Invest Radiol; 2022 May; 57(5):301-307. PubMed ID: 34839307
[TBL] [Abstract][Full Text] [Related]
15. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
[TBL] [Abstract][Full Text] [Related]
16. Disease-Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy.
Ueda M; Misumi Y; Nomura T; Tasaki M; Yamakawa S; Obayashi K; Yamashita T; Ando Y
Ann Neurol; 2024 Feb; 95(2):230-236. PubMed ID: 38053464
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M
Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864
[TBL] [Abstract][Full Text] [Related]
18. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
[TBL] [Abstract][Full Text] [Related]
19. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
[TBL] [Abstract][Full Text] [Related]
20. Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis.
Thimm A; Carpinteiro A; Oubari S; Papathanasiou M; Kessler L; Rischpler C; Malik RA; Herrmann K; Reinhardt HC; Rassaf T; Kleinschnitz C; Hagenacker T; Stettner M
J Neurol; 2023 Jul; 270(7):3483-3491. PubMed ID: 37014422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
